Biomarin Pharmaceutical Inc.

Bristol-myers Squibb Compnay

Christopher P Price

Augustus O Okhamafe

Daniel J Wendt

Michel Claude Vellard

Mika Aoyagi-Scharber

Shinong Long

Sianna Castillo

Stuart Bunting

Tianwei Chou

Clarence Yap

Sherry Bullens

Robert K Perrone

Ismat Ullah

Krishnaswamy Srinivas Raghavan

Rajesh Babulal Gandhi

Sachin S Chandran

Jaquan Kalani Levons

Robert Kevin Perrone

The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).

Variants of C-type natriuretic peptide

Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.

Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Growing community of inventors

Kentfield, CA, United States of America

Christopher P Price